In October 2012, a man in his 60s was hospitalized for the examination of ascites, and was diagnosed with gastric cancer and carcinomatous peritonitis. S-1+cisplatin (CDDP) therapy was administered as neoadjuvant chemotherapy; however, during therapy, he developed cerebral infarction. We suspected that the cerebral infarction was caused by a coagulation disorder owing to Trousseau's syndrome. After completing 5 courses of chemotherapy, total gastrectomy was performed. Thereafter, the treatment was changed to S-1+docetaxel(DTX), followed by nab-paclitaxel (PTX). Although cerebral infarction did not relapse after the administration of an anticoagulant agent, the patient died of gastric cancer 1 year and 5 months after the operation. Trousseau's syndrome is a coagulation disorder in cancer patients. Cerebral infarctions caused by Trousseau's syndrome have a high tendency to relapse, and the prognosis is poor. This syndrome should be kept in mind when treating cancer patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Myocardial bridging resulting in an atypical acute coronary syndrome in a young athlete: a case report.
Eur Heart J Case Rep
January 2025
Service de Cardiologie, Hôpital Trousseau, CHU de Tours, Avenue de la République, 37170 Chambray-Les-Tours, France.
Background: Myocardial bridging (MB) is considered a frequent and benign condition. However, some patients may experience symptoms. The recent ESC guidelines on sports participation provide guidance on the management of these symptomatic patients with MB but do not provide guidance in the presence of another cardiac pathology.
View Article and Find Full Text PDFAarskog-Scott syndrome: a clinical study based on a large series of 111 male patients with a pathogenic variant in and management recommendations.
J Med Genet
January 2025
Service de Génétique, Centre Hospitalier Régional Universitaire de Tours, Tours, France
Background: Aarskog-Scott syndrome (AAS) is a rare condition with multiple congenital anomalies, caused by hemizygote variants in the gene. Its description was based mostly on old case reports, in whom a molecular diagnosis was not always available, or on small series. The aim of this study was to better delineate the phenotype and the natural history of AAS and to provide clues for the diagnosis and the management of the patients.
View Article and Find Full Text PDFCurrent approach to diagnosis and management of low-phospholipid associated cholelithiasis syndrome.
Curr Opin Gastroenterol
January 2025
Reference Center for Inflammatory Biliary Diseases and Autoimmune Hepatitis, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Saint-Antoine Hospital, Assistance Publique - Hôpitaux de Paris; Sorbonne University, INSERM, Saint-Antoine Research Center (CRSA).
Purpose Of Review: Low phospholipid-associated cholelithiasis (LPAC) syndrome is a rare genetic form of intrahepatic cholesterol lithiasis, affecting mainly young adults. This review describes the recent advances in genetic and clinical characterization, diagnosis and management of LPAC syndrome.
Recent Findings: Recent publications report data from several retrospective cohorts.
JAGN1 (Jagunal-homolog1) is a ER-resident transmembrane protein which is part of the early secretory pathway and granulocyte colony-stimulating factor receptor mediated signaling. Autosomal recessively inherited variants in the JAGN1 gene lead to congenital neutropenia, early-onset bacterial infections, aphthosis and skin abscesses due to aberrant differentiation and maturation of neutrophils. In addition, bone metabolism disorders and a syndromic phenotype, including facial features, short stature and neurodevelopmental delay, have been reported in affected patients.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!